Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 12/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 12/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 0.89 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.89 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.89 |
| ▸ | XBP1 | P17861 | 2/20 | 0.89 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.89 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.89 |
| ▸ | NPC1 | O15118 | 1/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | ATM | Q13315 | 1/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.72 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.70 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.70 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.70 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12692505 | 0.96 | KMT2A (0.92) | MEN1KMT2AMAPTALDH1A1MAPK1 | |
| SCHEMBL12008780 | 0.90 | KMT2A (0.83) | MEN1KMT2AMAPTALDH1A1MAPK1 | |
| SCHEMBL5051688 | 0.88 | KMT2A (0.78) | MEN1KMT2AMAPTALDH1A1MAPK1 | |
| SCHEMBL5051690 | 0.88 | KMT2A (0.78) | MEN1KMT2AMAPTALDH1A1MAPK1 | |
| SCHEMBL12008563 | 0.86 | GPR35 (0.76) | MEN1KMT2AMAPTALDH1A1MAPK1 | |
| SCHEMBL12008621 | 0.86 | KMT2A (0.75) | MEN1KMT2AMAPTALDH1A1MAPK1 | |
| SCHEMBL12008794 | 0.84 | KMT2A (0.84) | MEN1KMT2AMAPTALDH1A1MAPK1 | |
| SCHEMBL11913693 | 0.84 | KMT2A (0.75) | MEN1KMT2AMAPTALDH1A1MAPK1 | |
| SCHEMBL11913684 | 0.83 | DDX3X (0.84) | MEN1KMT2AMAPTALDH1A1MAPK1 | |
| SCHEMBL12008953 | 0.83 | MEN1 (0.83) | MEN1KMT2AMAPTALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210299131-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NATIONAL INSTITUTES OF HEALTH | 2021-09-30 | — | — | US | disclosed |
| US-10953017-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | SOUTHERN RESEARCH INSTITUTE (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200171040-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | SOUTHERN RES INST (US) | 2020-06-04 | — | — | US | disclosed |
| US-20190083505-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NATIONAL INSTITUTES OF HEALTH | 2019-03-21 | — | — | US | disclosed |
| US-9980969-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | SOUTHERN RESEARCH INSTITUTE (US) | 2018-05-29 | — | — | US | disclosed |
| US-9980969-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | SOUTHERN RESEARCH INSTITUTE (US) | 2018-05-29 | — | — | US | disclosed |
| US-20160022691-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | SOUTHERN RES INST (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160022691-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | SOUTHERN RES INST (US) | 2016-01-28 | — | — | US | disclosed |
| US-9095596-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | SOUTHERN RESEARCH INSTITUTE (US) | 2015-08-04 | — | — | US | disclosed |
| US-9095596-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | SOUTHERN RESEARCH INSTITUTE (US) | 2015-08-04 | — | — | US | disclosed |
| US-20120245166-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | SOUTHERN RESEARCH INSTITUTE (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245166-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | SOUTHERN RESEARCH INSTITUTE (US) | 2012-09-27 | — | — | US | disclosed |
| WO-2011047129-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | SOUTHERN RESEARCH INSTITUTE (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022691-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NFKBIA, NFRKB, TFEB | MEN1 4432/4885KMT2A 1669/4885MAPT 54/4885 |
| US-20200171040-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NFKBIA, NFRKB, TFEB | MEN1 4526/4885KMT2A 1656/4885MAPT 56/4885 |
| US-20190083505-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NFKBIA, NFRKB, TFEB | MEN1 4526/4885KMT2A 1656/4885MAPT 56/4885 |
| US-20210299131-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NFKBIA, NFRKB, TFEB | MEN1 4526/4885KMT2A 1656/4885MAPT 56/4885 |
| US-20120245166-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NFKBIA, NFRKB, TFEB | MEN1 4526/4885KMT2A 1656/4885MAPT 56/4885 |
| US-10953017-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | NFKBIA, NFRKB, TFEB | MEN1 4526/4885KMT2A 1656/4885MAPT 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.